That's not true. Your paradigm is showing again: you probably look at this from a stock trader's perspective while any company interested will be looking at NanoLogix from a technology perspective. That technology perspective will include researching the patents and the research papers published by Battelle and the doctors in Houston. It will not include share price performance.
News 
Market Data 
Discover 
